Skip to content

Effects of intravenous lidocaine on colonoscopy under total intravenous anesthesia a double blind randomized controlled study

Effects of Intravenous Lidocaine on colonoscopy Under Total Intravenous Anesthesia: A double-blind Randomized Controlled Study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210902012
Enrollment
60
Registered
2021-09-02
Start date
2021-03-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A patient who required total intravenous anesthesia during colonoscopy colonoscopy TIVA lidocaine

Interventions

0.5% Lidocaine 0.3 ml/kg IV over 5 minutes then0.4 ml/kg/hr IV drip,NSS 0.3 ml/kg IV over 5 minutes then0.4 ml/kg/hr IV drip
Active Comparator Drug,Placebo Comparator Drug
Lidocaine,NSS

Sponsors

Faculty of Medicine Ramathibodi Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 18-75 years old patients 2. ASA physical status 1-3 3. colonoscopy under TIVA

Exclusion criteria

Exclusion criteria: 1. allergy to lidocaine and other drug that use in our protocol 2. cardiac arrhythmia 3. O2sat below 95% on room air 4. AST or ALT above 2 times from baseline 5. GFR below 45 ml/min/1.73m3 6. epilepsy 7. patients who cannot communicate. 8. patients who take hypnotic or analgesic drug longer than 3 months 9. patients with History of drug abuse or alocohol intoxication 10.patients refuse to participate in the research.

Design outcomes

Primary

MeasureTime frame
propofol dosage the end of colonoscopy under TIVA mg

Secondary

MeasureTime frame
hypoxia during endoscopy under TIVA number of events,apnea during colonoscopy under TIVA number of events

Countries

Thailand

Contacts

Public ContactPretimon Kimpee

Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University

pretimonkimpee@gmail.com0869782058

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026